Glucocorticoids inhibit superoxide (O°) generation by phagocytes through a mechanism that remains unclear. We investigated this effect by using dexamethasone on guinea pig alveolar macrophages. O2 generation was induced either by the calcium ionophore A23187, a potent stimulus of phospholipase A2, or by the protein kinase C activator, phorbol myristate acetate (PMA). Dexamethasone inhibited O2 generation initiated by A23187 by 50-55%. This inhibition required: (a) more than 45 min incubation and was maximal after 2 h; (b) glucocorticoid receptor occupancy; and (c) protein synthesis. The inhibitory effect of dexamethasone could not be explained by an interaction with the respiratory burst enzyme NADPH oxidase since O2 generation was only weakly affected upon PMA stimulation. Lipocortin I, a glucocorticoid inducible and phospholipase A2 inhibitory protein, inhibited O2 generation initiated by A23187 but failed to modulate the respiratory burst activated by PMA. These results were obtained with lipocortin I purified from mouse lungs, human blood mononuclear cells, and with human recombinant lipocortin I. We propose that lipocortin I is capable of inhibiting the activation of NADPH oxidase only when membrane signal transduction involves phospholipase A2. By mimicking the effect of dexamethasone, lipocortin I may extend its potential anti-inflammatory action to the partial control of the formation of oxygen reactive species by phagocytes.
Introduction
Activation of the superoxide-generating enzyme NADPH oxidase in phagocytes can be initiated either by stimuli involving binding to specific membrane receptors or by substances bypassing receptor interaction such as phorbol esters or calcium ionophores. Transmission of activation signals to the NADPH oxidase involves at least two distinct pathways (1, 2) , implying either phospholipase A2 (PLA2)' or protein kinase C activation (3) (4) (5) . Generation of superoxide (O°) by phagocytes can 1. Abbreviations used in this paper: AM, alveolar macrophages; PAF, platelet activating factor; PLA2, phospholipase A2; PMA, phorbol myristate acetate. be inhibited by in vivo or in vitro treatment by glucocorticoids, but their mechanism of action has not been clarified (6, 7) . Glucocorticoids also affect other phagocyte functions such as AA hydrolysis and, consequently, the synthesis of eicosanoids (7) (8) (9) . This particular effect of glucocorticoids was first attributed to the induction of a PLA2-inhibitory protein termed lipocortin I (8) (9) (10) . Other PLA2-inhibitory proteins with sequence homologies were then described and included in the lipocortin family although their induction by glucocorticoids remains to be established. Recently it has been reported that lipocortin I can inhibit cellular PLA2 of both guinea pig perfused lungs (1 1) and guinea pig alveolar macrophages (12) . We report here that in vitro treatment of guinea pig alveolar macrophages (AM) with dexamethasone inhibits O°generation. Since one of the NADPH oxidase activation pathways has been shown to involve PLA2, we investigated the possibility that lipocortin I could mimic the glucocorticoid inhibitory process using human recombinant lipocortin I or lipocortin I purified from either human blood mononuclear cells or mouse lungs.
Methods
Preparation of AM and incubation with dexamethasone. Hartley guinea pigs were anesthetized by intraperitoneal injection of sodium pentobarbitone (30 mg/kg). The trachea was cannulated and AM were obtained by repeated lung lavages with 5 ml sterile PBS, pH 7.4, at 37°C as previously described (13) , except that no lidocaine was added to the medium. Cells were washed and pelleted. Viability (> 90%) was assessed by trypan blue exclusion and the cell number was adjusted to 2 X 106 viable cells/ml of MEM (Eurobio, Paris, France) without phenol red supplemented with 0.5 mM CaC12; 0.25 mM MgCl2; 20 mM Hepes, and 0.5 g/liter glucose, pH 7.4, at 370C.
AM were incubated for 2 h in the presence of 5 ,M dexamethasone and stimulated. In some experiments cycloheximide (Sigma Chemical Co., St. Louis, MO) or RU486 (Roussel-Uclaf, Paris, France) was added to the cell suspension just before dexamethasone (Sigma Chemical Co.).
Superoxide measurement. Superoxide generation was assessed by the SOD-inhibiting reduction of cytochrome c, continuously monitored for 4 min at 550 nm with a spectrophotometer (Uvikon 860; Kontron Analytical, Redwood City, CA) thermostated at 37°C as previously described (3). Phorbol myristate acetate (PMA) and A23187 were obtained from Sigma Chemical Co.
Preparation oflipocortin I. Lipocortin I was purified from human blood mononuclear cells or from mouse lungs. The procedure for isolation of human mononuclear cells (70% lymphocytes, 30% monocytes) is reported in reference 14. Mouse lungs were isolated from thoracic cages, homogenized using a teflon potter, and sonicated. Proteins were extracted (14) and purified as previously described for human blood mononuclear cells (15) or mouse lungs (12) . The peak corresponding to lipocortin I was selected and analyzed in SDS-PAGE (14) . A single protein band at 40 kD was obtained with the preparation from mouse lungs and a single band at 35-38 kD with the protein from mononuclear cells. The two proteins exhibited PLA2 inhibitory activ-ity as assessed on porcine pancreatic PLA2 using membranes ofEscherichia coli labeled with [3H]oleic acid (16) . Western blot analyses were performed as described (14, 17) . The two proteins were recognized by the lipocortin I antiserum (15, 18) (20) , and the lipocortin II antiserum (provided by Biogen Corp.) has a low titer ofantibodies that recognize lipocortin I (18) . The lipocortin II and the 32-kD antisera (14) did not immunoreact with recombinant-, mouse lung-(12), or human blood mononuclear cell-lipocortin I (20) . The lipocortin III antiserum tested on recombinant lipocortin I and lipocortin I from human blood mononuclear cells did not immunoreact with these proteins (20) . Finally, our purified proteins cannot be similar to lipocortin IV since the lipocortin I antiserum raised against the recombinant protein does not immunoreact with lipocortin IV (R. B. Pepinsky, personal communication).
Before the use of the two purified lipocortin I's in biological experiments, the chromatographic buffer was removed by sequential microconcentrations on Centrcon 10 (Amicon Corp., Danvers, MA). The human recombinant lipocortin I (19) was kindly provided by Biogen Corp.
RIA of eicosanoids. Measurement of PGE2 and TXB2 were performed as previously described (21) .
Statistical analysis. The results were statistically analyzed using a paired t test.
Results
It has been reported that glucocorticoid treatment may modify the number of various membrane receptors (22) (23) (24) . Therefore, we decided to stimulate dexamethasone-treated AM with substances bypassing membrane receptors, the calcium ionophore A23187 and the protein kinase C activator PMA.
Generation of O2 induced by A23187 in AM was inhibited by dexamethasone (Table I ). The inhibitory effect was detected 45 min after dexamethasone addition and was maximal 2 h later. The dexamethasone effect was abolished when the protein synthesis inhibitor, cycloheximide, or the glucocorticoid receptor antagonist, RU486, was present (25; Table I ). RU486 or cycloheximide did not affect the generation ofO2 per se and did not enhance it when AM were stimulated with A23187 in the absence of dexamethasone (Table I) . At 10 ,sg/ml cyclo- To assess whether inhibition ofO°generation persists even after removal of glucocorticoids, cells were exposed to dexamethasone, then washed and incubated for an additional 2 h in the absence of dexamethasone before stimulation. During this particular procedure, which has been previously used for the study of the inhibitory effect of glucocorticoids on PLA2, the cells were still synthesizing proteins induced by glucocorticoids for 3-5 h (25). Under these conditions, generation of O2 by AM stimulated with A23187 was inhibited (Table II) to a similar extent as in the presence of dexamethasone (Table I) , indicating that preincubation with dexamethasone is sufficient to induce the inhibitory process. Stimulation of AM with PMA was only inhibited 9% by dexamethasone, whereas 50 ng/ml PMA or 8 AM A23187 provoked cell responses of similar magnitude (Table II) . This indicates that NADPH oxidase was probably not directly inhibited since O°generation was weakly modified upon PMA stimulation. Therefore, the inhibitory factor(s) seems most likely to interfere with the NADPH oxidase activation pathway initiated by A23187.
The calcium ionophore A23187 initiates AA hydrolysis which mainly results from PLA2 activation (26, 27 1,000 1 choo LIPOCORTIN 1 (ng/ml) for 30 min. Macrophages were stimulated with 8 X 10-6 M A23187 and O2 generation was recorded. Shown are the means±SD of three experiments. The statistical analysis was performed using a paired t test. From 10 ng/ml to 5 Ag/ml lipocortin I, the differences in superoxide production were significative when compared with control cells with P < 0.04.
As shown in Fig. 1, O2 generation by AM stimulated with A23187 was inhibited by lipocortin I purified from mouse lungs in a concentration-dependent manner from 10 ng/ml (2.5 X 10-10 M) to 1 ,ug/ml, which provided the maximal effect. The inhibitory effect was detected 15 Inhibition of PLA2 by extracellular lipocortin I was examined. Since inhibition of the release of AA by AM has been published elsewhere using the same preparations of lipocortin I as in the present work (see reference 12), here we only report the effect of 1 gg/ml lipocortin I on PGE2 synthesis (pg/106 cells in 1 ml, mean±SD, n = 3): (a) unstimulated cells: control, 345.3±35; lipocortin I, 222.3±23.6, P < 0.03; (b) A23187-stimulated cells: control, 865.3±79; lipocortin I, 611±45.6, P < 0.01).
The effects of three lipocortin I's purified from different sources were then compared. The human recombinant-, the mouse lung-, and the human blood mononuclear cell lipocortin I exhibited similar inhibitory ranges on the O2 generation initiated by A23187 (Fig. 2) . Upon PMA stimulation, none of the tested lipocortins inhibited O2 generation, suggesting that lipocortins did not interact with NADPH oxidase.
The effect of the mouse lung lipocortin I was investigated in the presence of another agonist that stimulates PLA2 (12, 29) , platelet-activating factor (PAF), a stimulus binding specific membrane receptors. As observed with A23187, lipocortin I inhibited°2 generation initiated by 5 X l0-7 M PAF (0.71 vs. 0.37 nmol 0i/min per 106 cells, mean of duplicate determinations).
Discussion
In the present paper we report that in vitro treatment of AM with dexamethasone is able to inhibit O-generation through a mechanism involving glucocorticoid receptor occupancy and Although this study further supports the involvement of PLA2 in the activation pathway of NADPH oxidase (3, 5, 30) , the relationship between these two enzymes was not investigated. It has been previously reported that AA and eicosanoids play a role in the activation of NADPH oxidase (3, 5, 28, 30, 31) , but their mechanisms of action are still unclear.
As previously described (8) (9) (10) (11) (12) , neither lipocortin I nor dexamethasone provided a total inhibition ofO°generation or AA hydrolysis. This may be explained either by the existence of a pool of lipocortin I-and dexamethasone-insensitive PLA2, or by the activation of several distinct phospholipid-degrading processes in macrophages stimulated with A23 187 or PAF (26, 29). Therefore, it is possible that the remaining fraction of O2 formation results from the hydrolysis of AA by enzymatic processes insensitive to lipocortin I and/or from the liberation of diacylglycerol by phospholipase C (although it is weakly stimulated by A23187 [26]) which is involved in NADPH oxidase activation through protein kinase C stimulation (1, 4, 32) .
It has been shown that treatment of macrophages with glucocorticoids induces the release of lipocortin (8, 33) . However, induction of its synthesis by glucocorticoids is still controversial although an increase in lipocortin I mRNA was reported (19) . Since lipocortin I is also a constitutive protein, another possible effect of glucocorticoids would be to provoke its secretion through a mechanism involving protein synthesis. When purified lipocortin I is applied extracellularly it may, therefore, mimic the effect of glucocorticoids. Indeed, some recent reports demonstrate an inhibition of PLA2 by extracellular lipocortin I (1 1, 12 ). These and our results are, however, in disagreement with the data of Northup and co-workers (34), who reported that extracellular lipocortin I does not inhibit PLA2 of mouse peritoneal macrophages, in contrast to what they observe by treating the cells with dexamethasone. In their experiments, lipocortin I was applied to the cells for only 15 min; therefore, we can question whether longer incubation time would have favored the action of lipocortin I.
The mechanism of action of extracellular lipocortin I has not yet been defined. It seems unlikely that a strongly polar 40-kD protein could enter the plasma membrane. The simplest model would be that lipocortin I interacts with a putative membrane receptor which could be PLA2 itself, assuming that PLA2 is a transmembrane protein. However, it has been proposed that the inhibition of PLA2 is dependent on the ability of lipocortin I to bind negatively charged phospholipids (14, 35) . Whether the low concentration of lipocortin I providing a biological effect (11, 12, this report) is compatible with this hypothesis remains to be elucidated. Albumin, which has also the ability to bind phospholipids, did, however, not modify the generation of O2, further suggesting a specific effect of lipocortin I.
Glucocorticoids are by far the most potent anti-inflammatory molecules active against virtually every type of inflammatory disease. Lipocortin, which has been recently defined as a "second messenger" of glucocorticoids (33) , can account in part for their anti-inflammatory action by controlling the synthesis of eicosanoids and PAF (33) . From the present study, the action of lipocortin I can be extended to the partial control of proinflammatory and tissue damaging oxygen reactive species.
In conclusion, we report that lipocortin I mimics the effect of dexamethasone and we propose that it could account for part of the action of glucocorticoids. We also confirm that lipocortin I is biologically active when applied extracellularly (1 1, 12) . In addition, our data further support the previously proposed critical role of PLA2 in the transduction of activation signals to NADPH oxidase (3, 5, 30) together with the involvement of a PLA2-independent activation pathway ofthe oxidase (1-3, 32) .
